Post-transplant diabetes: Diagnosis and management

Brian P Boerner, Vijay Shiva Swamy, Eric Wolatz, Jennifer Lynn Larsen

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Post-transplant diabetes mellitus (PTDM) is common after most types of solid organ transplantation, though the actual incidence is as yet unknown because of the use of different diagnostic criteria. PTDM is the result of individual risk factors as well as risk factors associated with the transplant itself, particularly immunosuppressants. Previously called New Onset Diabetes, in many cases inadequate screening for diabetes before transplant cannot assure that the diabetes is new after transplant. The most recent international consensus guidelines suggest diagnosis should be delayed until the patient is taking maintenance doses of immunosuppressants even if they require treatment in the immediate hospitalization. Criteria for diagnosis follow those of the American Diabetes Association and the World Health Organization, although hemoglobin A1C should not be used as the only screening test at least until one year after transplant because of its insensitivity for significant glucose intolerance in the transplant patient and setting. Management of PTDM is best done in a team setting, with an emphasis on glycemic control, dyslipidemia, and hypertension, and taking into consideration immunosuppressant regimens and potential drug side effects and interactions. While PTDM has been associated with changes in outcomes, these have and may continue to improve with improved diabetes care in and out of the hospital, and other changes in post-transplant care.

Original languageEnglish (US)
Pages (from-to)198-211
Number of pages14
JournalMinerva endocrinologica
Volume43
Issue number2
DOIs
StatePublished - Jun 2018

Fingerprint

Transplants
Diabetes Mellitus
Immunosuppressive Agents
Glucose Intolerance
Organ Transplantation
Dyslipidemias
Drug-Related Side Effects and Adverse Reactions
Hemoglobins
Hospitalization
Guidelines
Hypertension
Incidence

Keywords

  • Key words: transplantation - diabetes mellitus - immunosuppressive agents - renal insufficiency

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Post-transplant diabetes : Diagnosis and management. / Boerner, Brian P; Swamy, Vijay Shiva; Wolatz, Eric; Larsen, Jennifer Lynn.

In: Minerva endocrinologica, Vol. 43, No. 2, 06.2018, p. 198-211.

Research output: Contribution to journalReview article

Boerner, Brian P ; Swamy, Vijay Shiva ; Wolatz, Eric ; Larsen, Jennifer Lynn. / Post-transplant diabetes : Diagnosis and management. In: Minerva endocrinologica. 2018 ; Vol. 43, No. 2. pp. 198-211.
@article{e1fd8093d9244cf6bc1812db8a868ce5,
title = "Post-transplant diabetes: Diagnosis and management",
abstract = "Post-transplant diabetes mellitus (PTDM) is common after most types of solid organ transplantation, though the actual incidence is as yet unknown because of the use of different diagnostic criteria. PTDM is the result of individual risk factors as well as risk factors associated with the transplant itself, particularly immunosuppressants. Previously called New Onset Diabetes, in many cases inadequate screening for diabetes before transplant cannot assure that the diabetes is new after transplant. The most recent international consensus guidelines suggest diagnosis should be delayed until the patient is taking maintenance doses of immunosuppressants even if they require treatment in the immediate hospitalization. Criteria for diagnosis follow those of the American Diabetes Association and the World Health Organization, although hemoglobin A1C should not be used as the only screening test at least until one year after transplant because of its insensitivity for significant glucose intolerance in the transplant patient and setting. Management of PTDM is best done in a team setting, with an emphasis on glycemic control, dyslipidemia, and hypertension, and taking into consideration immunosuppressant regimens and potential drug side effects and interactions. While PTDM has been associated with changes in outcomes, these have and may continue to improve with improved diabetes care in and out of the hospital, and other changes in post-transplant care.",
keywords = "Key words: transplantation - diabetes mellitus - immunosuppressive agents - renal insufficiency",
author = "Boerner, {Brian P} and Swamy, {Vijay Shiva} and Eric Wolatz and Larsen, {Jennifer Lynn}",
year = "2018",
month = "6",
doi = "10.23736/S0391-1977.17.02753-5",
language = "English (US)",
volume = "43",
pages = "198--211",
journal = "Minerva Endocrinologica",
issn = "0391-1977",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Post-transplant diabetes

T2 - Diagnosis and management

AU - Boerner, Brian P

AU - Swamy, Vijay Shiva

AU - Wolatz, Eric

AU - Larsen, Jennifer Lynn

PY - 2018/6

Y1 - 2018/6

N2 - Post-transplant diabetes mellitus (PTDM) is common after most types of solid organ transplantation, though the actual incidence is as yet unknown because of the use of different diagnostic criteria. PTDM is the result of individual risk factors as well as risk factors associated with the transplant itself, particularly immunosuppressants. Previously called New Onset Diabetes, in many cases inadequate screening for diabetes before transplant cannot assure that the diabetes is new after transplant. The most recent international consensus guidelines suggest diagnosis should be delayed until the patient is taking maintenance doses of immunosuppressants even if they require treatment in the immediate hospitalization. Criteria for diagnosis follow those of the American Diabetes Association and the World Health Organization, although hemoglobin A1C should not be used as the only screening test at least until one year after transplant because of its insensitivity for significant glucose intolerance in the transplant patient and setting. Management of PTDM is best done in a team setting, with an emphasis on glycemic control, dyslipidemia, and hypertension, and taking into consideration immunosuppressant regimens and potential drug side effects and interactions. While PTDM has been associated with changes in outcomes, these have and may continue to improve with improved diabetes care in and out of the hospital, and other changes in post-transplant care.

AB - Post-transplant diabetes mellitus (PTDM) is common after most types of solid organ transplantation, though the actual incidence is as yet unknown because of the use of different diagnostic criteria. PTDM is the result of individual risk factors as well as risk factors associated with the transplant itself, particularly immunosuppressants. Previously called New Onset Diabetes, in many cases inadequate screening for diabetes before transplant cannot assure that the diabetes is new after transplant. The most recent international consensus guidelines suggest diagnosis should be delayed until the patient is taking maintenance doses of immunosuppressants even if they require treatment in the immediate hospitalization. Criteria for diagnosis follow those of the American Diabetes Association and the World Health Organization, although hemoglobin A1C should not be used as the only screening test at least until one year after transplant because of its insensitivity for significant glucose intolerance in the transplant patient and setting. Management of PTDM is best done in a team setting, with an emphasis on glycemic control, dyslipidemia, and hypertension, and taking into consideration immunosuppressant regimens and potential drug side effects and interactions. While PTDM has been associated with changes in outcomes, these have and may continue to improve with improved diabetes care in and out of the hospital, and other changes in post-transplant care.

KW - Key words: transplantation - diabetes mellitus - immunosuppressive agents - renal insufficiency

UR - http://www.scopus.com/inward/record.url?scp=85048692561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048692561&partnerID=8YFLogxK

U2 - 10.23736/S0391-1977.17.02753-5

DO - 10.23736/S0391-1977.17.02753-5

M3 - Review article

C2 - 28990741

AN - SCOPUS:85048692561

VL - 43

SP - 198

EP - 211

JO - Minerva Endocrinologica

JF - Minerva Endocrinologica

SN - 0391-1977

IS - 2

ER -